Poniard cancer news

Poniard discontinued its in-house preclinical research operations and reduced headcount by 8 (12%) to 57 to focus on developing and commercializing picoplatin. The company will continue to evaluate alternatives for its research programs, a process it began last December (see BioCentury, Dec. 8, 2008). ...